iTeos Therapeutics
Cambridge, US · Founded 2019 · Delaware corporation · 14 known investors
Find your way into iTeos Therapeutics
275 people in our graph share verified history with the iTeos Therapeutics team — schools, employers, funds. One of them is your warm intro.
Erez Kalirunlockedknows Michel Detheux · together at Vor Bio (overlapped)
×5knows the team · via Ona Therapeutics
knows the team · via Solvay Brussels School of Economics and Management
knows the team · via iTeos Therapeutics
knows the team · via MRM Health
×2knows the team · via Vor Bio
Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Founders & leadership
iTeos Therapeutics was founded in 2019 by Michel Detheux.
MD
Michel DetheuxinCo-founder, President & CEO2019–2026Michel Detheux holds a Ph.D. in Biochemistry from the Catholic University of Louvain and has over 30 years of experience in biotechnology and life sciences. He co-founded iTeos Therapeutics and served as its President and CEO, leading the company through clinical development and securing a major partnership with GlaxoSmithKline; he previously held scientific and business development roles at Ogeda and Ludwig Cancer Research.
DH
PB
Priyanka BelawatNamed on SEC filing
CB
JS
Jonathan SkipperNamed on SEC filing
Board
DB
AG
TV
Tim Van HauwermeirenBoard director
Investors · 14
VIVES PartnersWavre · $108K – $7.6M
6 Dimensions CapitalreportedGrand Cayman
Curative VenturesreportedDallas
Fund+reportedLeuven · $5.5M – $16.5M
HBM PartnersreportedZug · $5M – $50M
InvusreportedNew York
Janus Henderson InvestorsreportedLondon
MPM BioImpactreported · 3 sourcesBoston · $1M – $15Mvia Ansbert K. Gadicke · board
RA CapitalreportedBoston
RTW Investments L.P.reportedNew York
Also in the syndicate · 4
Boxer CapitalleadSFPISRIWVIVES Louvain Technology Fund
Reported raises · per SEC filings
Form D private placements$125.4M disclosed across 1 round · 2020
▶$125.4MraisedApr 2020 · 36 investors · Other TechnologyRule 506(b)
▶$125.4MraisedApr 2020 · 36 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David HallalDirector
- Detlev BiniszkiewiczDirector
- Michel DetheuxExecutive Officer, Director
- Priyanka BelawatDirector
- Ansbert GadickeDirector
- Tim Van HauwermeirenDirector
- CHris BuyseDirector
- Jonathan SkipperDirector
- Offering amount
- $125.4M
- Amount sold
- $125.4M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through iTeos Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does iTeos Therapeutics do?
- Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
- Who founded iTeos Therapeutics?
- iTeos Therapeutics was founded by Michel Detheux in 2019.
- Who are iTeos Therapeutics's investors?
- iTeos Therapeutics's investors include VIVES Partners, 6 Dimensions Capital, Curative Ventures, Fund+, HBM Partners, Invus, Janus Henderson Investors, MPM BioImpact and 2 more.
- How much funding has iTeos Therapeutics raised?
- iTeos Therapeutics has disclosed $125.4M raised across 1 round.
- Where is iTeos Therapeutics headquartered?
- iTeos Therapeutics is headquartered in Cambridge, US.